Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
What has happened to Onconova Therapeutics stock?
Since then, ONTX stock has decreased by 67.4% and is now trading at $1.76. View which stocks have been most impacted by COVID-19. Are investors shorting Onconova Therapeutics? Onconova Therapeutics saw a decrease in short interest in the month of February.
What does Onconova Therapeutics's P/E ratio mean?
The P/E ratio of Onconova Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Onconova Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Who is the new director of Corporate Development at Onconova?
NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.
Is onconova Therapeutics a good investment?
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What is going on with ONTX stock?
Onconova Therapeutics Inc (NASDAQ:ONTX) The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +691.37% increase from the last price of 1.39.
Did ONTX reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021.
What does onconova therapeutics do?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
What is a 1 for 15 reverse stock split?
In a 1-for-15 reverse stock split, each 100 shares previously purchased is now 7 shares. This split will require some changes to how you continue the Snider Investment Method® in this position.
Should I buy or sell Onconova Therapeutics stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There a...
What is Onconova Therapeutics' stock price forecast for 2022?
3 brokerages have issued 1 year price targets for Onconova Therapeutics' stock. Their forecasts range from $7.00 to $12.00. On average, they antici...
How has Onconova Therapeutics' stock price performed in 2022?
Onconova Therapeutics' stock was trading at $2.55 on January 1st, 2022. Since then, ONTX shares have decreased by 47.8% and is now trading at $1.33...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 65,800 shares, a decr...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast f...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0....
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number o...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Dr. Steven M. Fruchtman M.D. , CEO, Pres & Director (Age 71, Pay $903.45k)...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Greenwich LifeSciences (GLSI) , Evelo Biosciences (EVLO) , Epizyme (EPZM) , Da...
When will Onconova stock open in 2021?
Beginning at the open of trading on May 21, 2021, Onconova’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis. At Onconova’s 2021 reconvened annual meeting of stockholders on April 30, 2021, Onconova stockholders authorized the Company’s Board of Directors to amend the Tenth Amended and Restated Certificate ...
When did the authorized share decrease certificate of amendment become effective?
The Authorized Shares Decrease Certificate of Amendment became effective on May 20, 2021 upon the effectiveness of the Reverse Stock Split. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents ...
Is Onconova's expectations reasonable?
Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.
Is the Securities Exchange Act of 1934 a forward looking statement?
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.
Is there a fractional share in Onconova?
No fractional shares will be issued as a result of the reverse stock split. Instead, Onconova’s stockholders who otherwise would have been entitled to a fraction of a share, will receive a full share of common stock. If a holder of the tradable warrant would be entitled to receive a fraction of a share upon the exercise of the warrant, ...
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
1 ONTX Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Onconova Therapeutics Inc (ONTX) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Onconova Therapeutics Inc (ONTX) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Onconova Therapeutics Inc (ONTX) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Onconova Therapeutics Inc (ONTX) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
What is a strong weekly advance?
A strong weekly advance (especially when accompanied by increased volume) is a sought after metric for putting potential momentum stocks onto one's radar. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) are strong.
Does Zackstrade endorse or recommend investment strategies?
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
